XORTX Therapeutics (NASDAQ:XRTX – Get Free Report) and Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.
Valuation & Earnings
This table compares XORTX Therapeutics and Vivos Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| XORTX Therapeutics | N/A | N/A | -$2.66 million | ($2.63) | -0.82 |
| Vivos Therapeutics | $17.44 million | 0.41 | -$21.17 million | ($2.14) | -0.24 |
Institutional & Insider Ownership
0.2% of XORTX Therapeutics shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 6.9% of XORTX Therapeutics shares are owned by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares XORTX Therapeutics and Vivos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| XORTX Therapeutics | N/A | -150.01% | -106.53% |
| Vivos Therapeutics | -127.70% | -2,325.64% | -98.12% |
Volatility & Risk
XORTX Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 6.1, indicating that its share price is 510% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for XORTX Therapeutics and Vivos Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| XORTX Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
Vivos Therapeutics has a consensus price target of $2.80, suggesting a potential upside of 447.73%. Given Vivos Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than XORTX Therapeutics.
Summary
Vivos Therapeutics beats XORTX Therapeutics on 9 of the 13 factors compared between the two stocks.
About XORTX Therapeutics
Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
Receive News & Ratings for XORTX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XORTX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
